Eplontersen

WAINUA

Transthyretin-directed RNA Interaction

NADAC/unit N/A

No Shortage Tier 1: 0.9% PA Req: 3.6%

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Covered Lives

Generic Manufacturers

ASTRAZENECA AB

Explore in the Ecosystem

rxsaver.aiCompare prices for Eplontersen drfinder.aiFind doctors who prescribe Eplontersen rxnews.aiLatest news about Eplontersen

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.